HENDERSON, NV / ACCESSWIRE / February 22, 2019 / Below are several healthcare companies in the news leading the sector recently. A company in the sector that has not had news recently but according to their website, "has an open IND (Investigational New Drug) and has agreed with the FDA on a Phase 2 trial protocol that is targeted to start Q1 of 2019 (this quarter)," BioRestorative Therapies, Inc. (BRTX) has grabbed our attention. The company is developing therapies for the Global Chronic Low Back Pain Market (estimated of US$ 9.19 billion by 2025) and the Global Obesity Treatment Market ($15.6 billion by 2025.) *according to Grand View Research.
Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), ReWalk Robotics Ltd. (RWLK), Immune Design Corp. (NASDAQ: IMDZ), Valeritas Holdings Inc (NASDAQ: VLRX), and HEXO Corp. (NYSE American: HEXO).
BioRestorative Therapies, Inc. (BRTX) (Market Cap: $9.31M, Share Price: $0.7052), a life sciences company focused on stem cell-based therapies, is working on two major therapies their back-pain solution. BRTX-100 has shown positive results in both preclinical animal and human studies as a non-opioid chronic lower back pain treatment.
BRTX's obesity treatment, "ThermoStem," uses brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.
BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span US, Australia and Japan. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.
ReWalk Robotics Ltd. (RWLK) (Market Cap: $17.725M, Share Price: $0.2425) announced the pricing of a public offering of 19,000,000 ordinary shares, offered at a price to the public of $0.23 per share, for gross proceeds of approximately $4.37 million before deducting placement agent fees and other estimated offering expenses payable by ReWalk. The offering is expected to close on or about February 25, 2018, subject to customary closing conditions.
Immune Design Corp. (IMDZ) (Market Cap: $280.319M, Share Price: $5.82), a late-stage immunotherapy company, announced that they have entered into a definitive agreement with Merck, under which Merck, through a subsidiary, will acquire Immune Design for $5.85 per share in cash for an approximate value of $300 million.
Valeritas Holdings Inc (VLRX) (Market Cap: $45.418M, Share Price: $0.4544) announced positive clinical outcomes for its V-Go Wearable Insulin Delivery device compared to insulin pen devices for treating people with type 2 diabetes prescribed basal-bolus insulin therapy. Per the results, at the third and seventh month of V-Go use, patients experienced statistically significant reductions in both A1c levels and total daily doses of insulin. A1c levels decreased by 1.04 and 1.11, respectively from a baseline A1c of 9.1%. The average total daily dose of insulin decreased by 25 and 24 units per day, respectively, from a baseline dose of 82 units per day.
HEXO Corp. (HEXO) (Market Cap: $1.217B Share Price: $5.91), announced earlier this month that it has entered into a syndicated credit facility with Canadian Imperial Bank of Commerce, as Sole Bookrunner, Co-Lead Arranger and Administrative Agent and Bank of Montreal as Co-Lead Arranger and Syndication Agent. The deal consists of a C$50 million term loan and a C$15 million revolving loan, with an uncommitted option to increase the facility by up to C$135 million, subject to the satisfaction of certain customary legal and business conditions. Both loans mature in 2022.
Legal Disclaimer:
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. Regal Consulting has been compensated $50,000 cash for February services. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Full Legal Disclaimer Click Here.
Contact Information:
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: [email protected]
Phone: 1-702-720-6310
Country: United States
SOURCE: ACR Communication LLC